Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs

Inclusion Criteria: * HIV-infected adults receiving cART for at least 2 years * DTG/3TC/ABC as cART regimen in the previous 6 months. * CD4 counts higher than 200 cells per μL and virological suppression for at least 2 years (plasma HIV RNA \<20 copies per mL) Exclusion Criteria: * hepatitis C or B co-infection * unstable liver disease * renal impairment (estimated glomerular filtration rate \<50 mL per min), * gastrointestinal disorders that would affect the absorption of study treatment * current use of drugs with significant interactions with dolutegravir * current use of drugs with an impact on inflammation such as steroids. * hospitalization for acute illness within the previous 8 weeks * Pregnancy or breastfeeding. * Known resistance to DTG or 3TC * Active tuberculosis * Anal or rectal lesions impeding rectal biopsies * Decreased platelets count or coagulation disorder.